MAR 16, 2016 07:10 AM PDT

STING Agonists Induce Apoptosis in Malignant B Cells

WRITTEN BY: Xuan Pham

Wistar Institute researchers recently discovered a protein in the endoplasmic reticulum of the cell, called STING, can induce death of malignant B-cells. Because malignant B-cells are the cause of several lymphomas, new drugs that stimulate the production of STING could offer better directed treatments for conditions like chronic lymphocytic leukemia and multiple myeloma.
 

Image credit: Pixabay.com

Located on the cell’s endoplasmic reticulum (ER), STING or Stimulator of Interferon Genes, is involved in producing type 1 interferons, which are immune mediators that help regulate the immune system. Drugs that stimulate responses mediated by STING, called STING agonists, are known to boost production of interferons and thus enhance the immune responses. As such, STING agonists have been used as adjuvant therapies to complement and augment primary cancer treatments.
 
Recently, researchers found that STING agonists didn’t just work by augmenting the response of the main cancer drug; rather, they found that STING agonists had the potential to induce programmed cell death in both normal and malignant B-cells.
 
"In non-B cells, STING agonists stimulate the production of interferons, but since they induce apoptosis in B cells, these B cells do not live long enough to help boost the immune response," said Chih-Chi Andrew Hu, associate professor at the Wistar Institute and senior study-author. "We wanted to determine why STING agonists behave differently in normal and malignant B cells and how to extend this cytotoxic activity in malignant B cell leukemia, lymphoma and multiple myeloma."
 
To that end, the researchers identified an essential stress response pathway associated with the ER: the IRE-1/XBP-1 pathway. Cells lacking the necessary components IRE-1 or XPB-1 can’t produce interferons from STING stimulation. More crucially, the survival of B-cell lymphomas is dependent this pathway, which researchers showed was conveniently suppressed by STING agonists. Thus, by understanding the related complexity of this pathway, the researchers may have found a new way to treat lymphomas, using STING agonists as the primary therapy.
 

 
The team confirmed their results in mouse models of chronic lymphocytic leukemia and multiple myeloma, where they observed consistent cancer regression with the application of STING agonists. This validated their hypothesis that stimulation of STING suppresses the IRE-1/XBP-1 pathway, which increased apoptosis in cancerous B-cells.
 
“This specific cytotoxicity toward B cells strongly supports the use of STING agonists in the treatment of B cell malignancies," said Chih-Hang Anthony Tang, first study author. "We also believe that cytotoxicity in normal B cells can be managed with the administration of intravenous immunoglobulin that can help maintain normal levels of antibodies while treatment is being administered. This is something we plan on studying further."

Additional source: Wistar Institute press release

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
OCT 19, 2019
Health & Medicine
OCT 19, 2019
Does Cuttlefish Ink Hold a Cure for Cancer?
Using nanoparticles to deliver cancer-fighting compounds directly into tumors has been a hot research topic for the past few years. According to Lisa Ayga...
OCT 19, 2019
Cell & Molecular Biology
OCT 19, 2019
Investigating the Molecular Basis of Sex-related Differences in Cancer
There are sex-specific differences in the rate and lethality of various cancers....
OCT 19, 2019
Cell & Molecular Biology
OCT 19, 2019
How the Sun's Rays Damage the Skin
We all need sunlight, but it's very easy to get too much. Sunlight is the main source of the ultraviolet radiation we're exposed to....
OCT 19, 2019
Cancer
OCT 19, 2019
Electronic "nose" sniffs out the best cancer treatment
Can you imagine an electronic device that is capable of figuring out which lung cancer patients will respond best to immunotherapy? If so, now try to imagi...
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
Loading Comments...